Objective: The purpose of this study was to analyze a targeted screening program for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDdef) and clinical outcomes of G6PD-deficient vs G6PD normal newborns.
Introduction
Glucose-6-phosphate dehydrogenase deficiency (G6PDdef) is the most common enzyme defect in the world, affecting approximately 400 million people. 1 There are about 4.5 million infants born with the disorder yearly. 2 One of the most important clinical consequences of G6PDdef is neonatal hyperbilirubinemia that may cause kernicterus. 3 The World Health Organization recommends screening for G6PDdef where 3 to 5% of males are affected to detect deficient newborns and ensure that jaundice is recognized early and treated in a timely manner. 2 G6PDdef has now been recognized as a significant risk factor for severe hyperbilirubinemia in countries with a low overall incidence of the disorder such as Canada and the United Kingdom. 4, 5 The US Pilot Kernicterus Registry lists G6PDdef as the likely cause for kernicterus in 26 of its 125 cases (20.8%). 6 The overall incidence of G6PDdef in the United States is <3%, but 11 to 13% of African Americans are affected and other ethnic groups in the United States are at risk including South East Asian, Greek, Italian and Sephardic Jew. 7 Thus, certain regions of the country may have an incidence of the disorder that surpasses the World Health Organization threshold for screening. In 2005, global screening for G6PDdef was discussed at the Newborn Jaundice and Kernicterus Meeting in Siena, Italy. Participants concluded that G6PD screening should be available in most countries and performed in newborns of high-risk ethnic backgrounds with results available before birth hospitalization discharge to allow for family education and appropriate alteration of care and follow-up plans. 8 In 2006, there were 4284 births at MacDonald Women's Hospital University Hospitals Case Medical Center (UHC) in Cleveland, OH with 58.6% of infants born to black mothers. We calculated that 7% of all males born at UHC would have G6PDdef. As this exceeded the World Health Organization recommendation for G6PD screening, a pilot targeted cord blood newborn screening program for the disorder began on 1 May 2007. We sought to analyze the screening program and clinical outcomes of G6PD-deficient vs G6PD normal newborns identified by the UHC screening program.
Methods

Description of program
Each UHC hospital chart contains a demographics 'face sheet' that states patient race: black, white, Oriental, Hispanic, Native American or unknown. After birth, babies are assigned the same race as their mothers. However, the G6PDdef screening program relies on the completion of a questionnaire by all women admitted to UHC in labor. On the questionnaire, women self-identify at-risk ethnic background or family history of G6PDdef (Figure 1 ). Any 'yes' answer on the questionnaire and delivery of a male infant prompts cord blood collection in a Microtainer lavender plastic tube with Dipotassium EDTA (Becton Dickinson, Franklin Lakes, NJ, USA) for 'G6PD screen'. The questionnaire is then placed in the newborn's chart. If cord blood is not available, a heel-stick blood sample can be used. The laboratory uses 0.01 ml of blood and Trinity Biotech reagents (procedure no. 203; St Louis, MO, USA) for semiquantitative visual fluorescence screening to distinguish normal from grossly deficient samples. The tests are conducted daily Sunday to Thursday and twice on Friday to have results before discharge. Results are reported as 'normal' or 'abnormal'. Abnormal samples are considered grossly deficient and indicative of G6PDdef. Pediatric providers have been educated about the program and instructed that false normal results are possible due to elevated numbers of G6PD-rich leukocytes, platelets or reticulocytes. An educational handout was developed in conjunction with a pediatric hematologist and is given to all families of deficient newborns.
Usual clinical practice includes cord blood evaluation of blood type, Rh status and direct antibody test (DAT) for any infant born to a mother who is blood type O, Rh negative or has a positive indirect antibody test. Total bilirubin (TB) is measured daily transcutaneously (Minolta/Hill-Rom Air-Shields JM-103; Batesville, IN, USA) whereas serum TB testing is conducted at the discretion of the pediatrician. All infant charts contain a TB-monitoring tool that includes the Bhutani hour-specific risk nomogram 9 and the American Academy of Pediatrics (AAP) guidelines for phototherapy. 10 Decisions regarding use of phototherapy are made by the pediatrician. The majority of infants are discharged around Figure 1 G6PDdef risk-assessment questionnaire used at UHC. 
Analysis of screening program
The study protocol was approved by the UHC Institutional Review Board. A retrospective chart review was performed for all male newborns born at UHC and cared for on the Mother-Baby Postpartum/Normal Newborn floors from 1 May 2007 to 30 April 2008. Any infant having a G6PD screening test was included in the study group. Data collected from the study group charts included gestational age in completed weeks, sex, race from demographics face sheet, presence of risk-assessment questionnaire and indications for screening listed on questionnaire, date and time of birth, date of birth hospitalization discharge, cord blood evaluation results if applicable, and use of phototherapy during birth hospitalization. All TB levels obtained during birth hospitalization, transcutaneous TB or serum TB, were collected with hour of life performed. TB levels were plotted on the Bhutani hour-specific risk nomogram for each study group infant. Turnaround time for each G6PD screen sent was determined as the time from sample collection to the time the result was reported. Charts of any study group infant rehospitalized for hyperbilirubinemia were further assessed for presence of the major risk factors for the development of severe hyperbilirubinemia as per the 2004 AAP practice guideline including predischarge TB level in the high-risk zone on the Bhutani nomogram, blood group incompatibility or other known hemolytic disease, gestational age of 35 to 36 weeks, prior sibling who received phototherapy, jaundice observed in the first 24 h of life, cephalohematoma or significant bruising, exclusive breastfeeding and East Asian race. 10 Day of life and TB at rehospitalization and whether this TB met AAP phototherapy guideline, 10 as well as treatments during rehospitalization were also recorded.
Comparisons of clinical course between infants with abnormal and normal G6PDdef screening tests were carried out by w 2 analysis and unpaired t-test where appropriate. A P-value of <0.05 was considered significant.
Results
Analysis of screening program
During the study period, 1578 male infants of gestational ages 34 to 42 weeks were born at UHC and cared for on the Mother-Baby Postpartum/Normal Newborn floors. Of these, 1102 (69.8%) infants had G6PD tests sent. Two had G6PD quantitative assays ordered instead of the screening test. One of these infants was considered normal with a G6PD level of 550 U per 10 12 RBC (normal 146 to 376) and the other was diagnosed with G6PDdef (1 U per 10 12 RBC). Seven tests were cancelled due to collection error (0.6%), thus there were 1095 male infants successfully screened for the disorder. Of these, 973 were normal and 122 (11.1%) were abnormal and diagnosed with G6PDdef. Five infants with abnormal screening tests had quantitative G6PD enzyme assays performed at their pediatricians' discretion. All had confirmatory low G6PD levels of 52 to 87 U per 10 12 RBC. Cord blood evaluation was carried out in 621 of the 1095 infants screened for G6PDdef yielding 32 positive DAT (5.2%), 28 of these infants had ABO incompatibility and 4 had isoimmunization with anti-E, anti-c or anti-JK antibodies. Eight infants with positive DAT (25%) received phototherapy during their birth hospitalization. Six G6PD-deficient infants also had a positive DAT, and three received phototherapy. The hospital charge for the cord blood evaluation is $136 whereas the hospital charge for the G6PD screen is $39.
For our analysis, 1093 charts were available, including those of 971 G6PD normal and 122 G6PD abnormal infants. The majority of patients screened were black (80.9%) and 95.1% of the G6PD abnormal infants were black (Table 1) . Risk-assessment questionnaires were found in 354 of the 1093 charts reviewed (32.5%). The most frequent indication for screening per questionnaire was African-American ethnicity.
Within 24 h, 79% of all G6PD screening test results were reported and 97.8 and 99.6% were reported by 48 and 72 h, respectively ( Figure 2 ).
Clinical course of screened infants
The mean gestational age of the male infants found to be G6PD deficient was similar to the mean gestational age of those screened and normal (38.7 ± 1.48 weeks vs 38.7 ± 1.41 weeks, P ¼ 0.95). Average birth hospitalization length of stay was similar between the two groups (G6PD deficient 2.82 ± 1.94 days, G6PD normal 2.74±1.94 days, P ¼ 0.33). However, G6PD-deficient infants had higher TB levels throughout birth hospitalization with higher maximum (8.5±3.5 vs 7.3±3.4 mg per 100 ml, P<0.001), minimum (4.6 ± 2.2 vs 3.5 ± 2 mg per 100 ml, P<0.001) and predischarge (7.7 ± 3.2 vs 6.8 ± 3.1 mg per 100 ml, P ¼ 0.003) TB levels. Significantly more G6PD-deficient infants than G6PD normal infants had serum TB testing done (51/122, 41.8% vs 228/ Black  885  769  116  Oriental  22  21  1  White  128  126  2  Hispanic  3  3  0  Native American  2  2  0  Unknown  53  50  3  Total  1093  971  122 Abbreviation: G6PD, glucose-6-phosphate dehydrogenase.
Targeted screening program for G6PDdef ML Nock et al 973, 23.4%, P ¼ 0.001). When serum TB testing was conducted, G6PD-deficient infants had a higher mean peak serum TB than the G6PD normal infants (11.6±3.4 vs 10.3±3.8 mg per 100 ml, P<0.03). G6PD-deficient infants were more likely to have high-risk zone TB levels on the Bhutani nomogram (20.5 vs 7%, P<0.001) and to receive phototherapy (13.1 vs 3.4%, P<0.001) during their birth hospitalization compared to their G6PD normal counterparts. Nineteen infants who were screened for G6PDdef were rehospitalized for hyperbilirubinemia. Of these, 9 (47.4%) were G6PD deficient and 10 were G6PD normal (rehospitalization: G6PD deficient 9/122 ¼ 7.4%, G6PD normal 10/973 ¼ 1%). One G6PD-deficient infant was rehospitalized twice for hyperbilirubinemia. Upon his second admission, his TB was well below AAP phototherapy level and he received no treatment so the data from this hospitalization was not included in the analysis.
The rehospitalized infants did not differ in gestational age, birth hospitalization length of stay, need for phototherapy during birth hospitalization and day of life at readmission (Table 2 ). None had a positive DAT and none were treated with exchange transfusion. All had at least one major risk factor for the development of severe hyperbilirubinemia as per the AAP guideline. 10 The most frequent risk factor was exclusive breastfeeding (13/19), followed by G6PDdef (9/19). The G6PD-deficient infants had significantly more major risk factors than the G6PD normal infants (2.6 ± 1.4 vs 1.5±0.5, P<0.05, Table 2 ). However, hyperbilirubinemia requiring rehospitalization was not as predictable in G6PD-deficient newborns as in the G6PD normal infants. Of the rehospitalized G6PD-deficient infants, 6 of 9 had predischarge TB levels in the low-risk zone on the Bhutani risk nomogram. None had a high or high-intermediate risk predischarge TB level, whereas 5 of the 10 rehospitalized G6PD normal infants did. 9 The G6PD normal infants had significantly higher TB levels upon rehospitalization than those with G6PDdef (18.0 ± 3 vs 15.1 ± 2.6 mg per 100 ml, P<0.05, Table 2 ).
Discussion
The risk of severe hyperbilirubinemia in infants with G6PDdef has long been considered one of the most serious consequences of the disorder internationally.
3,11 Kaplan et al. 12 showed that AfricanAmerican male newborns in Chicago, IL with G6PDdef had significantly higher TB levels and need for phototherapy than those without, and the disorder is over-represented as a cause of kernicterus in the United States. 6 However, pediatricians in the United States rarely consider the disorder as a likely cause of neonatal hyperbilirubinemia. 13 In 2005, the AAP published a guideline for the management of hyperbilirubinemia providing clinicians with nomograms for the treatment of hyperbilirubinemia with phototherapy and exchange transfusion. 10 Use of these nomograms relies upon recognition of risk factors for significant hyperbilirubinemia in each infant, with late preterm infants with risk factors having the lowest thresholds for treatment. Many Targeted screening program for G6PDdef ML Nock et al institutions, including UHC, use cord blood screening for blood type and DAT to identify a major risk factor: isoimmune hemolytic disease. G6PDdef is also considered a major risk factor in the AAP guideline; however, screening in the United States is currently only performed in Washington, DC and Pennsylvania as part of state newborn metabolic screening. 8 This is through genetic testing for the mutations that would identify 90% of affected infants and results are typically available after 1 week of age. 8 Due to concern that UHC may have a significant number of newborns with G6PDdef and thus with a major risk factor for severe hyperbilirubinemia that was unrecognized, we implemented an inhospital screening program for newborn males of at-risk background. A targeted screening approach was used with a goal of having results before hospital discharge allowing for early delineation of risk factors.
In comparison of the two cord blood screening protocols at UHC for determination of major risk factors for newborn hyperbilirubinemia, the long-standing protocol of screening for isoimmune hemolytic disease had a lower yield at a higher cost than cord blood G6PDdef screening. Having either disorder or both disorders was associated with need for phototherapy during birth hospitalization.
Targeted screening for G6PDdef requires accurate assessment of ethnicity. 8 This was attempted at UHC through the G6PDdef riskassessment questionnaire. Only 32.5% of screened infant charts contained the questionnaire, which may be due to failure to administer or complete the questionnaire before birth, failure to insert the form into the newborn charts or because it was a new form at the time, the Medical Records department may have discarded some questionnaires in this first year of the program. Targeted screening could be carried out using the UHC demographics face sheet assignation of race. The majority of screened infants were black (80.9%) and the majority of affected infants were black (95.1%). However, using the face sheets and screening only black male infants would have missed 5% of all G6PD-deficient infants. With the questionnaire, we diagnosed G6PDdef in infants of Italian and Chinese ethnicity. Screening based on ethnic background instead of race is desirable, especially because the typical African variant, G6PD AÀ, has a milder course beyond the neonatal period compared to other variants that are more likely in people with the other ethnicities.
11
Screening of all males at UHC or universal screening would eliminate the need for assessment of ethnic background but would increase costs and test turnaround time. We have been very successful in providing the G6PDdef screening test results before discharge. This allows for families to be counseled regarding their infant's diagnosis and about hyperbilirubinemia, and enables clinicians to have a clear picture of risk factors for the development of severe hyperbilirubinemia and adjust care or follow-up plans accordingly before discharge. Accurate screening of all infants is not possible with the semiquantitative test being used. Sensitivity and specificity of a commercial fluorescent spot test for the identification of G6PD deficiency in male newborns was reported as 100 and 98%, respectively.
14 Thus, this test is reliable for detecting those newborns with severe deficiency such as hemizygous deficient males and homozygous deficient females; however, it is unreliable for detecting G6PDdef in heterozygous females. 15, 16 Quantitative enzyme assay is better than semiquantitative and genetic testing for diagnosis of G6PDdef in all infants. 17 However, G6PD quantitative enzyme assay is only available as a send-out test for UHC patients, thus turnaround time is generally greater than 72 h. So we elected to use the semiquantitative test and to screen only males due to concern about false normal results in heterozygous female infants who have been shown to have a similar risk of hyperbilirubinemia as homozygous deficient females. 16 We have bolstered prior evidence that G6PDdef is associated with neonatal hyperbilirubinemia in American infants. Newborn males at UHC with the disorder had higher bilirubin levels, were more likely to have a Bhutani nomogram high-risk zone TB, and to receive phototherapy than those without. Most notably, there was a seven-fold increased risk of rehospitalization for hyperbilirubinemia in G6PD-deficient newborns.
All of the 19 screened infants who were rehospitalized for hyperbilirubinemia had at least one of the major risk factors for development of severe hyperbilirubinemia listed in the 2004 AAP guideline. 10 The rehospitalized G6PD-deficient newborns had significantly more major risk factors than those rehospitalized and G6PD normal as they were known to be G6PD deficient. Because the risk of severe hyperbilirubinemia increases as more risk factors are present, 10 clinicians must be especially vigilant when caring for newborns with G6PDdef and other major risk factors for severe hyperbilirubinemia. Two of the nine readmitted G6PD-deficient neonates (22.2%) were of gestational ages 35 to 36 weeks. Rates of late-preterm births have steadily increased in the United States. 18, 19 Late-preterm infants are at increased risk of inefficient bilirubin conjugation and resultant hyperbilirubinemia that would be compounded by the increased baseline bilirubin production seen in G6PDdef, 20 thus G6PD-deficient late-preterm infants are of particular concern. It is also notable that pre-discharge TB levels in the rehospitalized G6PD-deficient newborns were not predictive of subsequent severe hyperbilirubinemia, with none of these infants having a high or high-intermediate risk zone pre-discharge TB.
Upon readmission, the G6PD normal infants had significantly higher TB levels at a similar age than those with G6PDdef. The percentage of infants with TB levels at or above their AAP guideline phototherapy level was greater in the G6PD-deficient infants than the G6PD normal infants; however, this did not reach statistical significance. This indicates that pediatricians at UHC, when provided the knowledge of their newborn patients' risk factors, are successfully recognizing that infants with risks such as G6PDdef are at higher risk for hyperbilirubinemia and require treatment at lower TB levels as per the AAP guideline.
Institutions may rely on cord blood type and DAT to identify newborns at risk for isoimmune hemolytic disease and hyperbilirubinemia. We have shown that identification of another major risk factor for hyperbilirubinemia, G6PDdef, can be achieved using cord blood with results before birth hospitalization discharge. We have diagnosed G6PDdef in 11.1% of male infants screened for the disorder using a targeted screening strategy. Similar programs to detect G6PDdef in American newborns should be considered, particularly in the US centers with an expected incidence of >3 to 5% of the male population where the disorder may be more common than isoimmunization. In setting up such programs, screening of all newborns through quantitative enzyme assay with results available before birth hospitalization discharge should be the goal. Such screening programs may contribute to timely identification of newborns at high risk for severe hyperbilirubinemia and the prevention of the sentinel event of kernicterus. 21 
